By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Personalized medicine software firm Proventys has raised nearly $3.3 million in an offering it hopes will bring in a total of $5.1 million, the firm said in a document filed with the US Securities and Exchange Commission.

The company did not say how the funds would be used.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.